Novo Nordisk shares fell 3.4% on Wednesday. Berenberg Bank downgraded the stock from "buy" to "hold" and lowered its price target.
Analysts cited intensifying competition from Eli Lilly in the obesity drug market as the primary driver. Berenberg noted that the market has fully priced in the potential of the Wegovy pill, leaving little room for positive surprises.
The decline occurred while broader U.S. equity markets advanced. This divergence indicates the sell-off was specific to the company and directly influenced by the analyst report.